31 / 33
Pembrolizumab discussion in 1L NSCLC?
Reck –NEJM 2016 * Brahmer – ASCO 2017, BrahmerWCLC 2017 *Reck – Lancet Oncol 2014 * Langer– Lancet Oncol 2016 * Patel –JCO 2013 * Lager – ASCO 2017 (A9084)
Pembrolizumab mono (Ph III)
CHEMOTHERAPY
10.3 months
Continued Pembrolizuamb beyond PD?
11 months
Better Pembrolizuamb + CT?
ANTIANGIOGENIC
4 months
PDL1 ≥ 50%--30%
Pembrolizuamb
+ CT (Ph II)
19 months (PFS not reported by PDL1 expression)
PDL1 all comers—100%
ANTIANGIOGENIC
4 months
Salvage (1) ?
OS
IMPACT
?
?